Rabies Vaccine SII
Establishment time : 1955
website : www.seruminstitute.com
Main Product : Rabies vaccine
Company Profile
Serum Institute of India is a globally recognized vaccine manufacturer with a strong focus on producing high-quality and affordable vaccines. Established in 1955, the company has become a key player in the global healthcare industry, particularly in the production of the rabies vaccine. With a large production capacity and a wide distribution network, Serum Institute of India caters to markets worldwide, ensuring access to life-saving vaccines for people in need.
Rabipur
Establishment time : 1980
website : www.rabipur.com
Main Product : Rabies vaccine
Company Profile
Rabipur is a leading pharmaceutical company specializing in the production of rabies vaccines. With a history dating back to 1980, we have established ourselves as a trusted provider of life-saving vaccines worldwide. Our large company size allows us to meet the demands of global markets and maintain a competitive edge in the industry.
Rabies Vaccine BP
Establishment time : 1988
website : www.rabiesvaccinebp.com
Main Product : Rabies vaccines
Company Profile
Rabies Vaccine BP is a leading manufacturer of rabies vaccines, established in 1988. We offer high-quality vaccines to protect against rabies and serve global markets. Our company is of medium size and faces strong competition in the vaccine industry. Visit our website at www.rabiesvaccinebp.com for more information.
Changchun Zhuoyi Biological Co., Ltd
Company Profile
Changchun Zhuoyi Biological Co., Ltd., located in Shuangyang Economic Development Zone of Changchun City, is a key vaccine manufacturer invested by Zhejiang SelCorning Biotechnology Co., Ltd. in Jilin Province, and a vice chairman unit of Zhejiang Chamber of Commerce in Jilin Province. The company was founded on January 27, 2005. Mr. Feng Xingfu, chairman and general manager of the company, graduated from the Department of Biology, University of Science and Technology of China, and has been engaged in the marketing and enterprise management of biological products since the 1980s. The company has a registered capital of one hundred and one million six hundred and ninety-two thousand seven hundred and eighty-four yuan, covers an area of 41600 square meters, and has the leading vaccine research and development and production capacity in China. Changchun Zhuoyi Biological Co., Ltd. is a new vaccine manufacturer integrating R&D, production and sales. At present, the biological products approved by the company are mainly Rabies Vaccine (Vero cell) for Human Use, Freeze-dried. The company successfully passed the two in one inspection at the end of 2016 and obtained the registration approval and GMP certificate, which was officially put into production in January 2017. The company's existing production workshop covers an area of about 5700 square meters, with a cumulative investment of 400 million yuan. At present, the maximum annual output is 1 million people. The second phase workshop has been completed at the end of 2018, and will be officially produced in 2020. By then, the production capacity can reach 4 million people. The company has nearly 2000 square meters of pilot scale research workshop, advanced equipment such as bioreactor, ultrafiltration system, AKTA purification workstation, fluorescence microscope, etc., which are used for virus culture, improvement of purification system and identification of recombinant protein. The company has maintained close scientific research cooperation with many scientific research institutions at home and abroad. At present, the company is developing a serum rabies vaccine and a broad-spectrum human papillomavirus vaccine jointly developed with the Institute of Basic Medicine of the Chinese Academy of Medical Sciences. It is planned to cooperate with Murdoch Children's Research Institute in Australia to develop the round vaccine project. At the same time, the company also actively explores the path of internationalization. At present, the company has started to register in the Philippines, Pakistan, Cambodia, Bangladesh, Mongolia, Uzbekistan and other countries. It is estimated that the export of finished products in some markets will be realized by 2020. The company's technical cooperation project with Australia is one of the company's many international cooperation projects. The company always adheres to the concept of "standardized management, quality first", and adheres to the core values of "honesty, diligence, innovation, preciseness, learning and happiness", so as to provide high-quality vaccine products to serve the health of the people.
